Yago Nieto
About
Yago Nieto is a scholar working on Oncology, Hematology and Molecular Biology.
According to data from OpenAlex, Yago Nieto has authored 242 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 130 papers in Oncology, 121 papers in Hematology and 57 papers in Molecular Biology. Recurrent topics in Yago Nieto's work include Multiple Myeloma Research and Treatments (55 papers), Hematopoietic Stem Cell Transplantation (54 papers) and Lymphoma Diagnosis and Treatment (41 papers). Yago Nieto is often cited by papers focused on Multiple Myeloma Research and Treatments (55 papers), Hematopoietic Stem Cell Transplantation (54 papers) and Lymphoma Diagnosis and Treatment (41 papers). Yago Nieto collaborates with scholars based in United States, Spain and Canada. Yago Nieto's co-authors include Elizabeth J. Shpall, Roy B. Jones, Richard E. Champlin, Scott I. Bearman, Chitra Hosing, Börje S. Andersson, Muzaffar H. Qazilbash, Pablo J. Cagnoni, Uday Popat and Anna E. Barón and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.
In The Last Decade
Yago Nieto
227 papers receiving 3.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Yago Nieto United States | 34 | 1.9k | 1.7k | 859 | 644 | 609 | 242 | 4.0k | ||
| J Garcı́a-Conde Spain | 35 | 984 0.5× | 2.0k 1.2× | 954 1.1× | 792 1.2× | 596 1.0× | 104 | 3.9k | ||
| Sergej Konoplev United States | 35 | 2.2k 1.2× | 1.4k 0.8× | 1.4k 1.6× | 1.2k 1.9× | 1.1k 1.8× | 154 | 4.6k | ||
| G.J. Ossenkoppele Netherlands | 34 | 1.6k 0.8× | 1.1k 0.7× | 783 0.9× | 677 1.1× | 607 1.0× | 84 | 3.3k | ||
| Anna Marina Liberati Italy | 31 | 1.3k 0.7× | 1.9k 1.1× | 1.1k 1.3× | 689 1.1× | 310 0.5× | 148 | 3.8k | ||
| Kazimierz Kuliczkowski Poland | 29 | 1.2k 0.7× | 1.2k 0.7× | 1.1k 1.3× | 1.1k 1.7× | 978 1.6× | 202 | 3.5k | ||
| Luciano J. Costa United States | 35 | 3.2k 1.7× | 2.4k 1.4× | 1.9k 2.2× | 619 1.0× | 651 1.1× | 256 | 4.8k | ||
| J. Thaler Austria | 37 | 1.1k 0.6× | 1.1k 0.6× | 991 1.2× | 512 0.8× | 558 0.9× | 125 | 4.1k | ||
| Dimitriοs Mavroudis Greece | 34 | 1.2k 0.6× | 2.0k 1.2× | 935 1.1× | 319 0.5× | 976 1.6× | 179 | 3.9k | ||
| Stefan Knop Germany | 33 | 1.9k 1.0× | 2.1k 1.2× | 1.9k 2.3× | 396 0.6× | 641 1.1× | 152 | 4.4k | ||
| Thomas Pabst Switzerland | 30 | 2.5k 1.4× | 1.2k 0.7× | 1.6k 1.9× | 713 1.1× | 376 0.6× | 180 | 4.3k |
Countries citing papers authored by Yago Nieto
Since
Specialization
Citations
This map shows the geographic impact of Yago Nieto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yago Nieto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yago Nieto more than expected).
Fields of papers citing papers by Yago Nieto
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Yago Nieto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yago Nieto. The network helps show where Yago Nieto may publish in the future.
Co-authorship network of co-authors of Yago Nieto
This figure shows the co-authorship network connecting the top 25 collaborators of Yago Nieto. A scholar is included among the top collaborators of Yago Nieto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yago Nieto. Yago Nieto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Nieto, Yago, Jeremy Ramdial, Benigno C. Valdez, et al.. (2025). Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma. Clinical Cancer Research. 31(6). 975–982.
2.
Borges-Sa, Marcío, María Aranda, Antònia Socías, et al.. (2025). Decoding Sepsis: A 16-Year Retrospective Analysis of Activation Patterns, Mortality Predictors, and Outcomes from a Hospital-Wide Sepsis Protocol. Journal of Clinical Medicine. 14(16). 5759–5759.
3.
Westin, Jason R., Loretta J. Nastoupil, Ranjit Nair, et al.. (2024). Factors associated with manufacturing failure of commercial CD19 CAR-T cell products for large b cell lymphoma (LBCL).. Journal of Clinical Oncology. 42(16_suppl). 7044–7044.
4.
Campbell, Matthew T., Shi‐Ming Tu, John C. Araujo, et al.. (2024). Doxorubicin, Paclitaxel, and Cisplatin (ATP) for Relapsed/Refractory Germ Cell Tumors. Clinical Genitourinary Cancer. 22(6). 102242–102242.
5.
Merryman, Reid W., Justin Rhoades, Kan Xiong, et al.. (2024). Comparison of whole‐genome and immunoglobulin‐based circulating tumor DNA assays in diffuse large B‐cell lymphoma. HemaSphere. 8(4). e47–e47.
6.
Marques‐Piubelli, Mario L., Do H. Kim, L. Jeffrey Medeiros, et al.. (2023). CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti‐CD30 CAR T‐cell therapy. Histopathology. 83(1). 143–148.
7.
Pasvolsky, Oren, Denái R. Milton, Mark R. Tanner, et al.. (2023). Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma. Transplantation and Cellular Therapy. 29(12). 757–762.
8.
Pasvolsky, Oren, Roland L. Bassett, Hina Khan, et al.. (2023). Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation. Cancer. 130(9). 1663–1672.
9.
Khawaja, Fareed, Joseph Sassine, Swaminathan P. Iyer, et al.. (2022). Herpesviruses Infections in CAR T Cell Recipients. Transplantation and Cellular Therapy. 28(3). S381–S382.
10.
Pasvolsky, Oren, Denái R. Milton, Mark R. Tanner, et al.. (2022). Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma. Transplantation and Cellular Therapy. 28(11). 752.e1–752.e6.
11.
Ragoonanan, Dristhi, et al.. (2022). Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective. Cancers. 14(12). 2912–2912.
12.
Lee, Hans C., Krina K. Patel, Sheeba K. Thomas, et al.. (2020). Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study. Clinical Lymphoma Myeloma & Leukemia. 20(5). e221–e238.
13.
Malek, Alexandre, Yago Nieto, Ariel D. Szvalb, et al.. (2019). Hepatitis B Virus-associated Liver Failure in a Patient With B-cell Non-Hodgkin Lymphoma After Anti-cancer Therapy Including Ibrutinib. Clinical Lymphoma Myeloma & Leukemia. 20(3). e124–e127.
14.
Ma, Hongbing, Uday Popat, Yago Nieto, et al.. (2019). Allogeneic Cord Blood Regulatory T Cells Can Prevent Graft Vs. Host Disease and Preserve Graft Vs Leukemia Effect: Update on Phase I/II Clinical Trial. Blood. 134(Supplement_1). 4547–4547.
15.
Rezvani, Katayoun, Betül Oran, Rohtesh S. Mehta, et al.. (2018). Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation. 25(3). 505–514.
16.
Mego, Michal, Hui Gao, Bang‐Ning Lee, et al.. (2012). Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. Journal of Cancer. 3. 369–380.
17.
Nieto, Yago & Elizabeth J. Shpall. (2009). High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted?. Current Opinion in Oncology. 21(2). 150–157.
18.
Nieto, Yago, et al.. (2004). Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous hematopoietic progenitor cell support. Biology of Blood and Marrow Transplantation. 10(6). 415–425.
19.
Nieto, Yago, Samia Nawaz, Elizabeth J. Shpall, et al.. (2004). Long-Term Analysis and Prospective Validation of a Prognostic Model for Patients with High-Risk Primary Breast Cancer Receiving High-Dose Chemotherapy. Clinical Cancer Research. 10(8). 2609–2617.
20.
Nieto, Yago, James J. Vredenburgh, Elizabeth J. Shpall, et al.. (2004). Phase II Feasibility and Pharmacokinetic Study of Concurrent Administration of Trastuzumab and High-Dose Chemotherapy in Advanced HER2+ Breast Cancer. Clinical Cancer Research. 10(21). 7136–7143.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by J Garcı́a-Conde Breakdown of academic impact, for papers by Sergej Konoplev Breakdown of academic impact, for papers by G.J. Ossenkoppele Breakdown of academic impact, for papers by Anna Marina Liberati Breakdown of academic impact, for papers by Kazimierz Kuliczkowski Breakdown of academic impact, for papers by Luciano J. Costa Breakdown of academic impact, for papers by J. Thaler Breakdown of academic impact, for papers by Dimitriοs Mavroudis Breakdown of academic impact, for papers by Stefan Knop Breakdown of academic impact, for papers by Thomas Pabst